Expression of CD44 and IDH1 R132H in Gliomas and their Prognostic Relevance

Jakovļevs, Arvīds; Vanags, Andrejs; Gardovskis, Jānis; Štrumfa, Ilze

doi:10.2478/prolas-2020-0048

Abstract

Gliomas are among the most common and aggressive primary brain tumours with dismal prognosis. A lot of research has been directed towards elucidating the molecular basis of these tumours, but few reliable prognostic markers are known. It is necessary to continue to study possible molecular factors that may be involved in development of gliomas or have a prognostic role. CD44 is a marker of neural stem cells and is involved in invasiveness of different tumours. In addition, IDH1 R132H mutant protein is expressed in secondary glioblastomas (GBMs) with much better prognosis. The goal of this study was to evaluate the expression and prognostic role of CD44 and IDH1 R132H in gliomas by immunohistochemistry. In this study, we found that CD44 expression was more prominent in glioblastomas than diffuse astrocytomas and it was not correlated with IDH1 mutational status. CD44 was not found to have a prognostic role in gliomas, in contrast with IDH1 R132H positive status, which was associated with better prognosis. Interestingly, higher CD44 expression values were associated with smaller size of GBMs and female gender indicating that the glioma stem cell population may be altered by gender specific factors and the growth rate of the tumour.

References

Anido, J., Saez-Borderias, A., Gonzalez-Junca, A., Rodon, L., Folch, G., Carmona, M. A., Prieto-Sanchez, R. M., Barba, I., Martinez-Saez, E., Prudkin, L. et al. (2010). TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell., 18 (6), 655–668.10.1016/j.ccr.2010.10.023
Search in Google Scholar Back to article
Bradshaw, A., Wickremsekera, A., Tan, S. T., Peng, L., Davis, P. F., Itinteang, T. (2016). Cancer stem cell hierarchy in glioblastoma multi-forme. Front Surg., 3, 21.
Search in Google Scholar Back to article
Brown, D. V., Daniel, P. M., D’Abaco, G. M., Gogos, A., Ng, W., Morokoff, A. P., Mantamadiotis, T. (2015). Coexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiforme. Oncotarget, 6 (8), 6267–6280.10.18632/oncotarget.3365
Search in Google Scholar Back to article
Cai, J., Zhu, P., Zhang, C., Li, Q., Wang, Z., Li, G., Wang, G., Yang, P., Li, J., Han, B., Jiang, C., Sun, Y., Jiang, T. (2016). Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. Oncotarget, 7 (13), 16384–16395.10.18632/oncotarget.7650
Search in Google Scholar Back to article
Christensen, B. C., Smith, A. A., Zheng, S., Koestler, D. C., Houseman, E. A., Marsit, C. J., Wiemels, J. L., Nelson, H. H., Karagas, M. R., Wrensch, M. R., Kelsey, K. T., Wiencke, J. K. (2011). DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J. Natl. Cancer Inst., 103 (2), 143–153.10.1093/jnci/djq497
Search in Google Scholar Back to article
Cohen, A., Holmen, S., Colman, H. (2013). IDH1 and IDH2 mutations in gliomas. Curr. Neurol. Neurosci. Rep., 13 (5), 345–345.10.1007/s11910-013-0345-4
Search in Google Scholar Back to article
Dzwonek, J., Wilczynski, G. M. (2015). CD44: Molecular interactions, signaling and functions in the nervous system. Front Cell Neurosci., 9, 175.10.3389/fncel.2015.00175
Search in Google Scholar Back to article
Gravendeel, L. A., Kloosterhof, N. K., Bralten, L. B., van Marion, R., Dubbink, H. J., Dinjens, W., Bleeker, F. E., Hoogenraad, C. C., Michiels, E., Kros, J. M., van den Bent, M., Smitt, P. A., French, P. J. (2010). Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. Hum. Mutat., 31 (3), E1186–1199.
Search in Google Scholar Back to article
Jijiwa, M., Demir, H., Gupta, S., Leung, C., Joshi, K., Orozco, N., Huang, T., Yildiz, V. O., Shibahara, I., de Jesus, J. A., Yong, W. H., Mischel, P. S., Fernandez, S., Kornblum, H. I., Nakano, I. (2011). CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One., 6 (9), e24217.10.1371/journal.pone.0024217
Search in Google Scholar Back to article
Juratli, T. A., Kirsch, M., Robel, K., Soucek, S., Geiger, K., von Kummer, R., Schackert, G., Krex, D. (2012). IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J. Neurooncol., 108 (3), 403–410.10.1007/s11060-012-0844-1
Search in Google Scholar Back to article
Kaaijk, P., Pals, S. T., Morsink, F., Bosch, D. A., Troost, D. (1997). Differential expression of CD44 splice variants in the normal human central nervous system. J. Neuroimmunol., 73 (1–2), 70–76.10.1016/S0165-5728(96)00167-1
Search in Google Scholar Back to article
Klank, R. L., Decker Grunke, S. A., Bangasser, B. L., Forster, C. L., Price, M. A., Odde, T. J., SantaCruz, K. S., Rosenfeld, S. S., Canoll, P., Turley, E. A., McCarthy, J. B., Ohlfest, J. R., Odde, D. J. (2017). Biphasic dependence of glioma survival and cell migration on CD44 expression level. Cell Rep., 18 (1), 23–31.10.1016/j.celrep.2016.12.024549814928052252
Search in Google Scholar Back to article
Le Mercier, M., Hastir, D., Moles Lopez, X., De Neve, N., Maris, C., Trepant, A. L., Rorive, S., Decaestecker, C., Salmon, I. (2012). A simplified approach for the molecular classification of glioblastomas. PLoS One, 7 (9), e45475.10.1371/journal.pone.0045475
Search in Google Scholar Back to article
Liu, Y., Han, S. S., Wu, Y., Tuohy, T. M., Xue, H., Cai, J., Back, S. A., Sherman, L. S., Fischer, I., Rao, M. S. (2004). CD44 expression identifies astrocyte-restricted precursor cells. Dev. Biol., 276 (1), 31–46.10.1016/j.ydbio.2004.08.018
Search in Google Scholar Back to article
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K. (2016). Astrocytic tumours. In: WHO Classification of Tumours of the Central Nervous System (Fourth Edition). WHO Press, Lyon, pp. 13–53.
Search in Google Scholar Back to article
Malik, N., Wang, X., Shah, S., Efthymiou, A. G., Yan, B., Heman-Ackah, S., Zhan, M., Rao, M. (2014). Comparison of the gene expression profiles of human fetal cortical astrocytes with pluripotent stem cell derived neural stem cells identifies human astrocyte markers and signaling pathways and transcription factors active in human astrocytes. PLoS One, 9 (5), e96139.10.1371/journal.pone.0096139
Search in Google Scholar Back to article
Mooney, K. L., Choy, W., Sidhu, S., Pelargos, P., Bui, T. T., Voth, B., Barnette, N., Yang, I. (2016). The role of CD44 in glioblastoma multiforme. J.Clin. Neurosci., 34, 1–5.10.1016/j.jocn.2016.05.012
Search in Google Scholar Back to article
Motomura, K., Natsume, A., Watanabe, R., Ito, I., Kato, Y., Momota, H., Nishikawa, R., Mishima, K., Nakasu, Y., Abe, T., Namba, H., Nakazato, Y., Tashiro, H., Takeuchi, I., Mori, T., Wakabayashi, T. (2012). Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci., 103 (10), 1871–1879.10.1111/j.1349-7006.2012.02377.x
Search in Google Scholar Back to article
Naor, D., Sionov, R. V., Ish-Shalom, D. (1997). CD44: Structure, function, and association with the malignant process. Adv. Cancer Res., 71, 241–319.10.1016/S0065-230X(08)60101-3
Search in Google Scholar Back to article
Naruse, M., Shibasaki, K., Yokoyama, S., Kurachi, M., Ishizaki, Y. (2013). Dynamic changes of CD44 expression from progenitors to subpopulations of astrocytes and neurons in developing cerebellum. PLoS One., 8 (1), e53109.10.1371/journal.pone.0053109353776923308146
Search in Google Scholar Back to article
Nobusawa, S., Watanabe, T., Kleihues, P., Ohgaki, H. (2009). IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res., 15 (19), 6002–6007.10.1158/1078-0432.CCR-09-071519755387
Search in Google Scholar Back to article
Ohgaki, H., Kleihues, P. (2013). The definition of primary and secondary glioblastoma. Clin. Cancer Res., 19 (4), 764–772.10.1158/1078-0432.CCR-12-300223209033
Search in Google Scholar Back to article
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I. M., Gallia, G. L. et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321 (5897), 1807–1812.
Search in Google Scholar Back to article
Petrey, A. C., de la Motte, C. A. (2014). Hyaluronan, a crucial regulator of inflammation. Front Immunol., 5, 101.10.3389/fimmu.2014.00101394914924653726
Search in Google Scholar Back to article
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., Williams, P. M., Modrusan, Z., Feuerstein, B. G., Aldape, K. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 9 (3), 157–173.10.1016/j.ccr.2006.02.01916530701
Search in Google Scholar Back to article
Pietras, A., Katz, A. M., Ekstrom, E. J., Wee, B., Halliday, J. J., Pitter, K. L., Werbeck, J. L., Amankulor, N. M., Huse, J. T., Holland, E. C. (2014). Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell., 14 (3), 357–369.10.1016/j.stem.2014.01.005399904224607407
Search in Google Scholar Back to article
Popova, S. N., Bergqvist, M., Dimberg, A., Edqvist, P. H., Ekman, S., Hesselager, G., Ponten, F., Smits, A., Sooman, L., Alafuzoff, I. (2014). Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology, 64 (3), 365–379.10.1111/his.12252467047524410805
Search in Google Scholar Back to article
Prochazka, L., Tesarik, R., Turanek, J. (2014). Regulation of alternative splicing of CD44 in cancer. Cell Signal., 26 (10), 2234–2239.10.1016/j.cellsig.2014.07.01125025570
Search in Google Scholar Back to article
Ranuncolo, S. M., Ladeda, V., Specterman, S., Varela, M., Lastiri, J., Morandi, A., Matos, E., Bal de Kier Joffe, E., Puricelli, L., Pallotta, M. G. (2002). CD44 expression in human gliomas. J. Surg. Oncol., 79 (1), 30–35.10.1002/jso.1004511754374
Search in Google Scholar Back to article
Sahlberg, S. H., Spiegelberg, D., Glimelius, B., Stenerlow, B., Nestor, M. (2014). Evaluation of cancer stem cell markers CD133, CD44, CD24: Association with AKT isoforms and radiation resistance in colon cancer cells. PLoS One., 9 (4), e94621.10.1371/journal.pone.0094621399740324760019
Search in Google Scholar Back to article
Shankar, A., Kumar, S., Iskander, A., Varma, N. R. S., Janic, B., deCarvalho, A., Mikkelsen, T., Frank, J. A., Ali, M. M., Knight, R. A., Brown, S., Arbab, A. S. (2014). Subcurative radiation significantly increases cell proliferation, invasion, and migration of primary glioblastoma multiforme in vivo. Chin J. Cancer, 33 (3), 148–158.10.5732/cjc.013.10095396621524016393
Search in Google Scholar Back to article
Si, D., Yin, F., Peng, J., Zhang, G. (2020). High expression of CD44 predicts a poor prognosis in glioblastomas. Cancer Manag. Res., 12, 769–775.10.2147/CMAR.S233423700685932099472
Search in Google Scholar Back to article
Sosunov, A. A., Wu, X., Tsankova, N. M., Guilfoyle, E., McKhann, G. M., Goldman, J. E. (2014). Phenotypic heterogeneity and plasticity of isocortical and hippocampal astrocytes in the human brain. J. Neurosci.,34 (6), 2285–2298.10.1523/JNEUROSCI.4037-13.2014391387224501367
Search in Google Scholar Back to article
Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P. et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17 (1), 98–110.10.1016/j.ccr.2009.12.020281876920129251
Search in Google Scholar Back to article
Wang, C., Wang, Z., Chen, C., Fu, X., Wang, J., Fei, X., Yan, X., Xu, R. (2020). A small-molecule CD44 dimerizing inhibitor for glioblastoma treatment. Brit. J. Pharmacol., 11 (19), 491–498.
Search in Google Scholar Back to article
Ward, P. S., Cross, J. R., Lu, C., Weigert, O., Abel-Wahab, O., Levine, R. L., Weinstock, D. M., Sharp, K. A., Thompson, C. B. (2012). Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogen,31 (19), 2491–2498.10.1038/onc.2011.416327113321996744
Search in Google Scholar Back to article
Xu, H., Tian, Y., Yuan, X., Wu, H., Liu, Q., Pestell, R. G., Wu, K. (2015). The role of CD44 in epithelial–mesenchymal transition and cancer development. OncoTargets Ther.,8, 3783–3792.
Search in Google Scholar Back to article
Xu, Y., Stamenkovic, I., Yu, Q. (2010). CD44 attenuates activation of the Hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res., 70 (6), 2455–2464.10.1158/0008-5472.CAN-09-2505284007320197461
Search in Google Scholar Back to article
Ylagan, L. R., Quinn, B. (1997). CD44 expression in astrocytic tumors. Mod. Pathol., 10 (12), 1239–1246.
Search in Google Scholar Back to article

Expression of CD44 and IDH1 R132H in Gliomas and their Prognostic Relevance

Abstract

Paradigm

My account